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Glycopeptide-intermediate Staphylococcus aureus (GISA) and, in particular, heterogeneous GISA (hGISA)
are difficult to detect by standard MIC methods, and thus, an accurate detection method for clinical practice
and surveillances is needed. Two prototype Etest strips designed for hGISA/GISA resistance detection (GRD)
were evaluated using a worldwide collection of hGISA/GISA strains covering the five major clonal lineages. A
total of 150 strains comprising 15 GISA and 60 hGISA strains (defined by population analysis profiles-area
under the curve [PAP-AUC]), 70 glycopeptide-susceptible S. aureus (GSSA) strains, and 5 S. aureus ATCC
reference strains were tested. For standardized Etest vancomycin (VA) MIC testing, the modified Etest
macromethod with VA and teicoplanin (TP) strips tested with a heavier inoculum using brain heart infusion
agar (BHI) and two glycopeptide screening agar plates (6 g/ml VA/BHI and 5 g/ml Mueller-Hinton agar
[MHA]) were tested in parallel with the two new Etest GRD strips: a VA 32 (0.5-g/ml)-TP 32 (0.5-g/ml)
double-sided gradient (E-VA/TP) with one prototype overlaid with a nutrient (E-VA/TPS) to enhance the
growth of hGISA. The Etest GRD strips were tested with a standard 0.5-McFarland standard inoculum using
MHA and MHA plus 5% blood (MHB) and were read at 18 to 24 and 48 h. The interpretive MIC cutoffs used
for the new Etest GRD strips at 24 and 48 h were as follows: for GISA, TP or VA, >8, and a standard VA MIC
of >6; for hGISA, TP or VA, >8, and a standard VA MIC of <4. The results on MHB at 48 h showed that
E-VA/TPS had high specificity (94%) and sensitivity (95%) in comparison to PAP-AUC and was able to detect
all GISA (n 15) and 98% of hGISA (n 60) strains. In contrast, the glycopeptide screening plates performed
poorly for hGISA. The new Etest GRD strip (E-VA/TPS), utilizing standard media and inocula, is a simple
and acceptable tool for detection of hGISA/GISA for clinical and epidemiologic purposes.
The first reports of glycopeptide-intermediate Staphylococ-
cus aureus (GISA) strains raised some complex and challeng-
ing questions with respect to their clinical significance, meth-
ods for the detection of these phenotypes, and the definition of
this “resistance,” all issues that persist today (10, 23). Addi-
tionally, a heterogeneous form of the resistance (heteroge-
neous GISA [hGISA]) is frequently seen in which only a small
proportion of the population (approximately 106) expresses
the resistant phenotype, creating even further detection dilem-
mas (10). It took over 10 years for heterogeneous methicillin-
resistant S. aureus (hMRSA) to be considered the same phe-
notype (and genotype) as MRSA, and this may prove to be the
case for hGISA, as well (4).
hGISA and GISA have been the subjects of many recent
reviews covering their mechanisms of resistance, clinical rele-
vance, treatment challenges, and detection methods (3, 7, 9, 15,
19, 20, 22, 23). It now appears that hGISA and GISA have
common structural and clinical features, leading many re-
searchers to feel that they are almost identical and should be
reported as such (12). Generally speaking, both hGISA and
GISA possess thickened cell walls, are associated with pro-
longed glycopeptide therapy and low glycopeptide serum con-
centrations, and often share a number of genetic expression
markers, e.g., atl and mrpB (8, 15, 18, 27, 28, 30). More im-
portantly, there are an increasing number of studies alluding to
the clinical significance of hGISA and its association with van-
comycin (VA) failures (5, 13, 14, 27).
The current differentiation of hGISA from GISA appears to
imply that GISA possesses a homogeneously VA-resistant
population, in contrast to hGISA. However, population studies
of strains with reduced susceptibility to VA (MICs, 2 to 16
g/ml) have shown that this is indeed not the case and that
GISA strains often present with a nonhomogeneous or hetero-
geneous VA kill curve. The obvious difference seen between
hGISA and GISA is that the GISA isolates more often pro-
duce enough of the subpopulation expressing the intermediate
level of “resistance” that the cells will grow on VA at 4 g/ml
when tested with standard inoculum equivalent to 0.5 McFarland
standard. Accordingly, there is much debate over whether the
current CLSI VA-intermediate breakpoint of 4 to 8 g/ml is
appropriate for detecting all hGISA/GISA phenotypes. A re-
cent study in which VA MICs for 20 GISA, 157 hGISA, and
106 non-GISA isolates were determined indicated that the
current intermediate breakpoint of 4 g/ml should be reduced
to 2 g/ml to better identify the hGISA/GISA strains (31). This
notion is further supported by the CDC, which has revised its
S. aureus/VA algorithm, accommodating VA-intermediate
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S. aureus stains that do not express high levels of VA resistance
(http://www.cdc.gov/ncidod/dhqp/ar_visavrsa.html). This initia-
tive was adopted by the CLSI in 2005, and appropriate amend-
ments were subsequently made to Tables 2C, M2, and M7 on
their website (http://www.clsi.org).
Since their advent nearly 10 years ago, many methods have
been advocated for detecting hGISA/GISA (6). Automated
methods have been modified to try to detect high-level VA-
resistant S. aureus (MIC  32 g/ml); however, these methods
struggle to detect GISA and are inappropriate for detecting
hGISA (1, 2). As disk diffusion testing was quickly recognized
to be unsuitable (16), other methods have been proposed, such
as glycopeptide screening plates (6) and various population
studies (11, 29). Other techniques, such as the modified Etest
method (macromethod [E-M]), have also been introduced, but
E-M requires nonstandard media (brain heart infusion [BHI])
and 2.0-McFarland standard inoculum, i.e., variations that are
beyond the standard susceptibility-testing praxis (26). Accord-
ingly, we investigated a new Etest hGISA/GISA resistance
detection (GRD) strip (E-VA/teicoplanin [TP]), one with a
growth nutrient incorporated into the strip (E-VA/TPS) and
one without. The GRD strip uses a standard inoculum and
agar, and in this study, we tested it against an international
collection of hGISA/GISA/non-GISA strains comprising dif-
ferent multilocus sequence-typing profiles and established ge-
netic lineages (17).
MATERIALS AND METHODS
Strains. The following reference organisms were used and were tested in
quintuplicate: S. aureus ATCC 29213 and 25923 (non-MRSA), ATCC 43300
(MRSA), ATCC 700698 (Mu3; hGISA), and ATCC 700699 (Mu50; GISA). The
clinically derived test strains comprised the following: 15 GISA, 60 hGISA
(defined by a positive population analysis profile-area under the curve [PAP-AUC]),
and 70 glycopeptide-susceptible S. aureus (GSSA) strains. These isolates com-
prised an international collection of unique strains (different clones) including all
five major endemic MRSA clonal lineages (17).
Media and antibiotics. BHI and Mueller-Hinton agar (MHA) were obtained
from BBL (Becton Dickinson, Cockeysville, MD). VA and TP antibiotic powders
were obtained from Fagron (Barsbuttel, Germany) and Molcan Corp. (Rich-
mond Hill, Canada), respectively.
E-M. E-M was performed as described by Walsh et al. (26). A suspension of
colonies from an overnight culture on a blood plate was prepared in Mueller-
Hinton (MH) broth, and the turbidity was adjusted to 2.0 McFarland standard,
after which 200 l of the suspension was pipetted and evenly streaked out on the
surface of a 90-mm BHI agar plate. The Etest standard procedure for MIC
testing of VA was performed using an inoculum suspension in 0.9% saline (0.5
McFarland standard) that was streaked onto MHA plates (BBL). After the
plates were dried for approximately 10 min, Etest strips (AB Biodisk, Solna,
Sweden) for VA (0.016 to 256 g/ml) and TP (0.016 to 256 g/ml) were applied
to the BHI plate and VA was applied to the MH plate. The agar plates were
incubated at 35°C for 18 to 24 and 48 h and were read by two different laboratory
technicians.
Etest GRD strip. The two new Etest prototype strips evaluated were a VA
32-0.5-g/ml–TP 32-0.5-g/ml double-sided gradient (E-VA/TP), with one pro-
totype having a nutrient incorporated into the strip (E-VA/TPS) to enhance
the growth of hGISA. Both strips were tested with standard inoculum (0.5
McFarland standard) using MHA (BBL)  5% blood (MHB) and read at 18 to
24 and 48 h. The endpoints read from the Etest GRD strips should not be
regarded as true MICs, but rather as modified results with interpretive cutoffs
defined for the phenotypic detection of glycopeptide resistance phenotypes in S.
aureus. The preliminary interpretive cutoffs used for the Etest GRD prototype
strips read at 24 and 48 h were as follows: GISA, E-M values for TP or VA of8
and a standard VA MIC of 6; hGISA, E-M values for TP or VA of 8 and a
standard VA MIC of 4.
VA screening plate. The VA (6 g/ml) BHI screening plate (21, 24, 26)
recommended by the CDC (http://www.cdc.gov) was used. All plates were spot
inoculated with 10 l of an inoculum suspension prepared with growth from an
overnight blood agar plate, with a turbidity equivalent to 0.5 McFarland stan-
dard. The plates were incubated for 48 h, and growth was reported after both 24
and 48 h.
TP screening plate. The TP (5 g/ml) MHA screening plate recommended by
the Comite´ de l’Antibiogramme de la Socie´te´ Franc¸aise de Microbiologie (CA-
SFM) (http://www.sfm.asso.fr) was used. All plates were spot inoculated with 10
l of an inoculum suspension prepared with growth from an overnight blood agar
plate, with a turbidity equivalent to 2 McFarland standard. The plates were
incubated for 48 h, and growth was reported after both 24 and 48 h.
PAP-AUC. The method described by Wootton et al. was used (29) for PAP-
AUC. After 24 h of incubation in tryptone soya broth (Oxoid, Basingstoke,
Hampshire, United Kingdom), an undiluted culture and dilutions of 1/108 and
1/105 were inoculated, using a spiral plater (Don Whitley, Shipley, United King-
dom), onto BHI agar (Oxoid) plates containing 0.5, 1, 2.5, 4, and 8 g/ml of VA.
Colonies were counted after 48 h of incubation. The number of CFU/ml was
plotted against the VA concentration using GraphPad Prism software (San
Diego, CA). The AUC was plotted for each test strain and compared with the
curves for Mu3, Mu50, and S. aureus ATCC control strains. A ratio was then
calculated by dividing the AUC of the test strain by the AUC of Mu3. The isolates
used had their PAP-AUCs calculated prior to commencement of the study; however,
a random sample (50 isolates) was chosen to ensure that the PAP-AUC value, i.e.,
the hGISA/GISA phenotype, had been maintained.
FIG. 1. E-VA/TP and E-VA/TPS with MHA and MHB for S. aureus ATCC 29213. (Left panel) MHA, E-VA/TP (left) and E-VA/TPS
(right). (Right panel) MHB.
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Statistical analysis. The performance of each method in detecting hGISA/
GISA was evaluated by comparison with the PAP-AUC ratio. Each method was
assessed for its specificity and sensitivity in discriminating hGISA/GISA from
GSSA, as previously described (26). The specificity was based on the number of
correct negative results, i.e., the true number of GSSA strains that were correctly
identified. The sensitivity was based on the number of hGISA/GISA strains that
were correctly identified.
RESULTS
Figures 1 to 3 show examples of results with the new Etest
VA/TPS strips for S. aureus ATCC 29213, ATCC 700698
(Mu3), and ATCC 700699 (Mu50), respectively. Table 1 shows
the MIC range for each of the methods. Typically, the GRD
values for the negative control GSSA strain, S. aureus ATCC
29213, for VA and TP varied between 0.5 and 1 g/ml on both
MHA and MHB. For hGISA and GISA, the MIC ranges were
higher after 48 h, and the resistance was enhanced by the
presence of both the blood and the growth supplement (Table
1). S. aureus ATCC 700698 (Mu3) gave low VA values and
discernibly high TP values (32 g/ml), and small-colony vari-
ants (SCVs) were clearly visible within the TP inhibition el-
lipses on MHA and MHB. S. aureus ATCC 700699 (Mu50)
gave high VA values (12 g/ml) compared to Mu3, with SCVs
clearly visible in the VA inhibition ellipse, particularly on
MHB. Predictably, the Mu50 GISA phenotype had a very high
TP value (32 g/ml) and almost no inhibition ellipse.
Table 2 compares the sensitivity and specificity of the Etest
GRD strips (E-VA/TP  S) with the E-M for the 150 PAP-
AUC phenotypically characterized strains. For the detection of
hGISA/GISA, the E-VA/TPS strip tested on MHB and read
at 48 h had the highest sensitivity (94%) and was comparable
to the E-M. The addition of 5% blood to MHA (MHB) in-
creased the 48-h detection sensitivity for E-VA/TP and E-VA/
TPS from 80 to 89% and from 84 to 94%, respectively. The
sensitivity for the 24-h reading was appreciably lower than that
for 48 h, confirming the need for extended incubation to op-
timize the detection of glycopeptide resistance. After 48 h of
incubation, all methods gave a specificity of 95 to 96%.
The VA screening plate, VA/BHI, missed most hGISA/
GISA strains (overall sensitivity, 27%) (Table 2), with 12%
sensitivity for hGISA and 87% sensitivity for GISA. The CA-
FIG. 2. E-VA/TP and E-VA/TPS with MHA (left) and MHB (right) for S. aureus ATCC 700698 (Mu3; hGISA).
FIG. 3. E-VA/TP and E-VA/TPS with MHA (left) and MHB (right) for S. aureus ATCC 700699 (Mu50/GISA).
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SFM screening plate (TP/MHA) was better than VA/BHI, with
an overall sensitivity of 65% and a specificity of 95%. However,
while it was able to detect most GISA strains (93% sensitivity),
it had a sensitivity of only 58% for hGISA strains.
All strains were independently tested in triplicate under
blind conditions to examine the robustness of each method.
Table 3 summarizes the reproducibility of the Etest GRD
strips (E-VA/TP and E-VA/TPS) and E-M to the two agar
screening plates. For the GISA strains (n  15), the E-VA/TP
and E-VA-TPS strips and E-M had 100% reproducibility
compared to the agar screens, VA/BHI and TP/MHA, which
had 87 and 93%, respectively. The screening plates were un-
reliable for the detection of hGISA (n 60), with VA/BHI and
TP/MHA having poor reproducibilities of 12% and 58%, re-
spectively. The best performance for the repeated detection of
hGISA was found with the E-VA/TPS strip on MHB, which
had a reproducibility of 98% at 48 h. The addition of blood to
MHA proved very effective in increasing the reproducibility of
hGISA detection from 81 to 95% and from 89 to 98% for the
E-VA/TP and EVA/TPS strips, respectively (Table 3).
DISCUSSION
The increasing debate over the clinical significance of GISA,
and in particular hGISA, has been compounded by the diffi-
culty of detecting them. The clinical failure attributable to
glycopeptide use may in part be due to their physical and
chemical properties, high protein binding, and potentially in-
sufficient drug levels at the infection site due to poor pharma-
cokinetics properties of the drug and difficulties in optimizing
the dose and dosing regimen relative to concentration-related
toxicities of the drugs (25). However, despite subtherapeutic
drug levels, it is now known that staphylococci can respond to
the presence of low levels of glycopeptide, which can subse-
quently select for low-level resistance. This type of heteroge-
neous and variable resistance in staphylococci, which is ex-
pressed at various frequencies within the population, is not
detectable by either disk diffusion (16, 27) or automated sus-
ceptibility testing systems (8, 24), a phenomenon recognized by
TABLE 2. Sensitivity and specificity of E-VA/TP/-S on MHA and
MHB, and E-M for detection of hGISA/GISA phenotypes
characterized by PAP-AUC
Test Medium
Time of
reading
(h)
Detection (%)
Sensitivity Specificity
Etest GRD strips
E-VA/TP MHA 24 53 100
48 80 95
MHB 24 55 100
48 89 95
E-VA/TPS MHA 24 63 100
48 84 95
MHB 24 70 100
48 94 95
E-M BHI/2 McFarland 24 80 87
48 94 96
Agar screens VA/BHI 48 27 100
TP/MH 48 65 95
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numerous expert groups, including the CDC (http://www
.cdc.gov/ncidod/dhqp/ar_visavrsa.html), CLSI (http://www.clsi
.org), the British Society for Antimicrobial Chemotherapy
(http://www.bsac.org.uk), and CA-SFM (http://www.sfm.asso
.fr). To address the limitations of disk diffusion and automated
systems, agar screening plates have been developed as simple
alternatives to screen for hGISA/GISA strains, since PAP
methods are highly specialized and unsuitable for use in clin-
ical laboratories. The PAP-AUC used as the reference method
in this study, while labor-intensive, is sensitive. The VA/BHI
plate, initially developed for VA resistance screening of en-
terococci, is commercially available and is widely used in the
United States. However, this study and various others have
clearly shown that this method is poor at detecting hGISA and
occasionally fails to detect GISA strains. TP, a more sensitive
marker for the detection of hGISA/GISA, is not available as a
commercial reagent in the United States, thus precluding the
TP/MHA plate as a viable option for screening of hGISA/
GISA.
The E-M was first introduced as a potential screening
method for detecting hGISA/GISA and thereafter was further
investigated in a controlled study (26). The new Etest GRD
strip with double-sided VA and TP concentration gradients
across seven dilutions (E-VA/TP) was designed to be used with
normal media and at a standard inoculum, circumventing some
of the perceived problems that arose with the macromethod.
GISA and hGISA strains are notoriously slow growing, and
their standard features are a thickened cell wall and a pleo-
morphic appearance, often involving SCVs. Accordingly, in
order to detect all SCVs, a growth supplement that enhances
their growth and thus their detection has been added. The two
prototypes (E-VA/TP and E-VA/TPS) were examined using
the standard inoculum of 0.5 McFarland standard on two dif-
ferent agar plates (MHA and MHB) that are readily available
in the clinical laboratory. The sensitivity at 48 h is greater than
that at 24 h (Table 2), as the SCVs are large enough to be seen
with the naked eye and are visible as a light growth within the
Etest ellipse (Fig. 1 to 3). Given that VA is often used for an
extended period (some studies report hGISA being treated for
a period of 18 weeks), we feel that the 48-h incubation period
for improved sensitivity is appropriate and does not overtly
affect the clinical outcome (27). Results for E-VA/TPS read
after 18 to 24 h of incubation, if positive for hGISA/GISA, can
be reported as such, although negative results should be con-
firmed after 48 h of incubation, since sensitivity was highest at
48 h, detecting all GISA (n  15) and 98% of hGISA (n  60)
strains on MHB.
Clinicians and laboratories alike are becoming increasingly
aware that patients on long-term VA therapy and cases of
recurrent MRSA bacteremia (5, 12) may signal the presence
and potential spread of hGISA/GISA strains. The extent of the
problem is still unknown, as laboratories are not equipped with
appropriate and sensitive test methods that can reliably detect
these phenotypes in their clinical routines. Here, we have pre-
sented a new method, the Etest GRD strip with VA and TP,
that performs as well as the E-M and the reference PAP-AUC
assay but with the simplicity of a standard routine diagnostic
test that can be used daily for clinical and epidemiological
purposes.
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